Welcome to our dedicated page for Atrion news (Ticker: ATRI), a resource for investors and traders seeking the latest updates and insights on Atrion stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atrion's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atrion's position in the market.
Atrion Corporation (NASDAQ: ATRI) reported second-quarter 2022 revenues of $48.9 million, a 14% increase from $42.7 million in Q2 2021. Operating income rose to $11.0 million, up $1.2 million, with net income at $9.3 million, up $424 thousand. Diluted earnings per share increased to $5.20 compared to $4.88 in the same period last year. Despite higher sales and administrative expenses of $1.6 million, gross margin improved from 42% to 43%. The company expects double-digit revenue growth and a 20% rise in operating income for the second half of 2022.
Atrion Corporation (NASDAQ: ATRI) has declared a quarterly dividend of $1.95 per share. This dividend is set to be paid on June 30, 2022, to stockholders of record by the close of business on June 15, 2022. The company specializes in developing and manufacturing medical products. This decision reflects Atrion's commitment to returning value to its shareholders through consistent dividend payments.
Atrion Corporation (NASDAQ: ATRI) reported a 20% increase in revenues for Q1 2022, totaling $47.1 million, compared to $39.2 million in Q1 2021. Operating income rose by 15% to $10.3 million, while net income increased by 10% to $8.5 million. Diluted earnings per share were $4.71, up from $4.22 the previous year. Despite challenges from the pandemic and rising costs, the company anticipates completing a facility expansion by summer 2023 to support new product launches. Cash and investments stand at $77.8 million, with no debts reported.
Atrion Corporation (NASDAQ: ATRI) reported its Q4 2021 results, showing revenues of $40.3 million, up 25% from Q4 2020. Net income rose to $8.1 million, with diluted EPS at $4.50, a $0.48 increase year-over-year. For the full year 2021, revenues reached $165.0 million, a 12% increase, and net income was $33.1 million, reflecting a 3% rise. Challenges included higher labor costs and supply chain issues, impacting operational efficiency. CEO David Battat anticipates double-digit growth in 2022, driven by their MPS 3 technology and continued R&D investments.
Atrion Corporation (NASDAQ: ATRI) has declared a quarterly dividend of $1.95 per share on its outstanding shares of Common Stock. This dividend is set to be paid on March 31, 2022 to stockholders of record as of the close of business on March 15, 2022. Atrion specializes in developing and manufacturing products for medical applications, reinforcing its commitment to providing returns to shareholders while focusing on growth in the medical sector.
Atrion Corporation (NASDAQ: ATRI) has declared a quarterly dividend of $1.95 per share, scheduled for payment on December 15, 2021. This dividend is for stockholders recorded as of the close of business on December 1, 2021. Atrion specializes in developing and manufacturing products for medical applications, signaling its ongoing commitment to provide value to shareholders.
Atrion Corporation (NASDAQ: ATRI) reported Q3 2021 revenues of $42.9 million, up 27% from $33.8 million in Q3 2020. Net income rose to $8.3 million, an increase of $1.1 million year-over-year, with diluted EPS at $4.58. The growth was supported by a 42% increase in Cardiovascular revenues. Despite rising costs impacting gross profit margins, which fell to 41% from 44% in the prior year, the company anticipates a 25% revenue increase in Q4 2021. Cash and investments totaled $78.1 million, after repurchasing shares worth $6.5 million.
Atrion Corporation (NASDAQ: ATRI) announced the immediate election of Maria Sainz to its Board of Directors. With over 20 years in the medical device sector, Sainz has held CEO roles at successful medtech start-ups, two of which were acquired by major companies. Her experience includes leadership positions at Guidant Corporation and integration efforts post-acquisition by Boston Scientific. Additionally, she serves on the boards of public companies ShockWave Medical and Avanos Medical.
Atrion Corporation (Nasdaq ATRI) announced an increase in its quarterly cash dividend from $1.75 to $1.95 per share. The Board of Directors declared this dividend on its outstanding shares of Common Stock. The dividend will be payable on September 30, 2021, to stockholders of record as of September 15, 2021. Atrion Corporation specializes in developing and manufacturing products primarily for medical applications.
Atrion Corporation (NASDAQ: ATRI) reported second-quarter revenues of $42.7 million, up from $38.0 million in Q2 2020. Net income rose to $8.9 million compared to $8.6 million year-over-year, with diluted earnings per share at $4.88, up from $4.68. The company noted a 9% increase in revenues and a 10% increase in operating income sequentially. Looking ahead, Atrion expects approximately a 25% increase in sales and operating income for the remainder of 2021, barring COVID-19 disruptions. Cash and investments totaled $80.0 million as of June 30, 2021.
FAQ
What is the current stock price of Atrion (ATRI)?
What is the market cap of Atrion (ATRI)?
